| Similar Articles |
|---|
 |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.   |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
April 11, 2011
Brian Orelli |
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected. |
The Motley Fool
January 17, 2012
Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
The Motley Fool
July 31, 2008
Brian Lawler |
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? |
The Motley Fool
January 13, 2010
Brian Orelli |
JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in. |
The Motley Fool
December 15, 2009
Brian Orelli |
Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
June 18, 2008
Brian Lawler |
Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive. |
The Motley Fool
October 18, 2006
Rich Duprey |
FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note. |
The Motley Fool
May 22, 2007
Brian Lawler |
Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
The Motley Fool
August 27, 2007
Rich Duprey |
Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo. |
The Motley Fool
May 30, 2006
Rich Duprey |
NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders? |
The Motley Fool
April 17, 2007
Rich Duprey |
Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors? |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
January 24, 2005
Rich Duprey |
No Taking Chances With Reminyl Johnson & Johnson's daffodil-extract Alzheimer's treatment yanked from market. Shares are off only 1% or so. |
The Motley Fool
August 29, 2008
Brian Orelli |
A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
April 12, 2004
Brian Gorman |
Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors. |
The Motley Fool
February 15, 2006
Rich Duprey |
Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note. |
The Motley Fool
December 20, 2007
Brian Orelli |
What Was That Clinical Trial For? EPIX Pharmaceuticals initiates a phase 2A study of its Alzheimer's disease drug, PRX-03140, to get safety and tolerability information. Instead, it got good efficacy data. |
The Motley Fool
March 17, 2006
Rich Duprey |
Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
January 17, 2008
Brian Orelli |
EPIX's Epic Oops The EPIX clinical trial data on their Alzheimer's medication wasn't as positive as it first appeared. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
November 2, 2006
Rich Duprey |
Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
July 9, 2009
Brian Orelli |
Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable. |
The Motley Fool
September 9, 2009
Brian Orelli |
Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa |
